First quarter
- Net sales reached
SEK 9.4 (13.0) million. -
The operating result totaled
SEK -18.4 (-14.4) million. -
Earnings per share, basic and diluted, were
SEK -0.11 (-0.09). -
Cash flow from operating activities totaled
SEK -7.3 (-12.2) million.
CEO Comment
"Sales for the first quarter were lower than the same period last year, which in its entirety is due to the low partner sales. In the Swedish market, sales were up by 21% compared to the same quarter last year, and our market share continues to increase. During the quarter, ColdZyme was MDR certified as one of the first cold products in
Significant events during the quarter
- On
February 16, 2024 , the Board of Directors decided to carry out a rights issue, with preferential rights for existing shareholders, ofSEK 27.4 million before issue expenses. The rights issue was 72.7 percent subscribed with the support of subscription rights and 7.9 percent without the support of subscription rights. The remaining part of the rights issue was subscribed through guarantee commitments fromEnzymatica's three largest owners, through wholly or partly owned companies, and the Chairman of the Board and CEO. After issue expenses, the company receivesSEK 25.5 million . -
ColdZyme® was certified in
March 2024 under the EU MDR (Class III) regulation. The MDR replaces the EU's Medical Device Directive (MDD) and imposes stricter requirements on the evidence for clinical validity, safe design and market surveillance. ColdZyme is one of the first cold and flu products to be certified under the regulation.
Significant events after the quarter
- No significant events were reported after the quarter.
Other events during and after the quarter
- On
March 2, 2024 , ProfessorGlen Davison presented the first results from his ongoing clinical trial on ColdZyme at theIOC 's 7thWorld Conference on Prevention of Injury and Illness in Sport, the premier international conference on clinical aspects of sports and exercise medicine. The British Journal of Sports Medicine published an abstract about the ongoing clinical trial on ColdZyme at theUniversity of Kent . The initial results from the study showed that ColdZyme significantly reduced the quantity of rhinovirus and symptoms of sore throat compared with placebo. The final results of the study are expected in the first half of 2024.Enzymatica will participate in the Global Health Campaign initiative that brings together consumer health and life science companies. At the end ofMay 2024 , participating companies will join researchers and experts for the Global Health Summit inGeneva .-
The Swedish government has tasked the
Swedish Agency for Health Technology Assessment and Assessment of Social Services with the task of investigating the state of knowledge regarding the effect of products that are claimed to combat colds. The assignment must be reported by1 September 2024 at the latest.
The full report is available on: www.enzymatica.com/investors/financial-reports
This information is information that
For more information, please contact:
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com
For more information, please visit www.enzymatica.se.
https://news.cision.com/enzymatica-ab/r/interim-report-q1-2024--mdr-certification-opens-up-great-commercial-opportunities,c3967653
https://mb.cision.com/Main/18091/3967653/2759265.pdf
https://mb.cision.com/Public/18091/3967653/b2ca5530e5223012.pdf
(c) 2024 Cision. All rights reserved., source